Candel Therapeutics, Inc. CADL Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Candel Therapeutics, Inc. (CADL) reported short- and long-term operating lease liabilities of -$108K in Q1 2026.
- How has Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities increased by 20.6% year-over-year, from -$136K to -$108K.
- What is the long-term trend for Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s short- and long-term operating lease liabilities has grown at a 3.1% compound annual growth rate (CAGR), from -$464K to -$509K.